These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
369 related articles for article (PubMed ID: 30554729)
1. Expression of erythropoietin messenger ribonucleic acid in wild-type MED12 uterine leiomyomas under estrogenic influence: new insights into related growth disparities. Asano R; Asai-Sato M; Matsukuma S; Mizushima T; Taguri M; Yoshihara M; Inada M; Fukui A; Suzuki Y; Miyagi Y; Miyagi E Fertil Steril; 2019 Jan; 111(1):178-185. PubMed ID: 30554729 [TBL] [Abstract][Full Text] [Related]
2. Aberrant expression of erythropoietin in uterine leiomyoma: implications in tumor growth. Asano R; Asai-Sato M; Miyagi Y; Mizushima T; Koyama-Sato M; Nagashima Y; Taguri M; Sakakibara H; Hirahara F; Miyagi E Am J Obstet Gynecol; 2015 Aug; 213(2):199.e1-8. PubMed ID: 25724399 [TBL] [Abstract][Full Text] [Related]
3. HMGA2 and MED12 alterations frequently co-occur in uterine leiomyomas. Galindo LJ; Hernández-Beeftink T; Salas A; Jung Y; Reyes R; de Oca FM; Hernández M; Almeida TA Gynecol Oncol; 2018 Sep; 150(3):562-568. PubMed ID: 30017537 [TBL] [Abstract][Full Text] [Related]
4. MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists. Nagai K; Asano R; Sekiguchi F; Asai-Sato M; Miyagi Y; Miyagi E Am J Obstet Gynecol; 2023 Feb; 228(2):207.e1-207.e9. PubMed ID: 36150519 [TBL] [Abstract][Full Text] [Related]
5. Vitamin D as an effective treatment in human uterine leiomyomas independent of mediator complex subunit 12 mutation. Corachán A; Trejo MG; Carbajo-García MC; Monleón J; Escrig J; Faus A; Pellicer A; Cervelló I; Ferrero H Fertil Steril; 2021 Feb; 115(2):512-521. PubMed ID: 33036796 [TBL] [Abstract][Full Text] [Related]
6. MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma. Bertsch E; Qiang W; Zhang Q; Espona-Fiedler M; Druschitz S; Liu Y; Mittal K; Kong B; Kurita T; Wei JJ Mod Pathol; 2014 Aug; 27(8):1144-53. PubMed ID: 24390224 [TBL] [Abstract][Full Text] [Related]
7. Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays. Yatsenko SA; Mittal P; Wood-Trageser MA; Jones MW; Surti U; Edwards RP; Sood AK; Rajkovic A Fertil Steril; 2017 Feb; 107(2):457-466.e9. PubMed ID: 27889101 [TBL] [Abstract][Full Text] [Related]
8. MED12 mutation frequency in unselected sporadic uterine leiomyomas. Heinonen HR; Sarvilinna NS; Sjöberg J; Kämpjärvi K; Pitkänen E; Vahteristo P; Mäkinen N; Aaltonen LA Fertil Steril; 2014 Oct; 102(4):1137-42. PubMed ID: 25108465 [TBL] [Abstract][Full Text] [Related]
9. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors. Mäkinen N; Kämpjärvi K; Frizzell N; Bützow R; Vahteristo P Mol Cancer; 2017 Jun; 16(1):101. PubMed ID: 28592321 [TBL] [Abstract][Full Text] [Related]
10. MicroRNAs involved in the HMGA2 deregulation and its co-occurrence with MED12 mutation in uterine leiomyoma. Mello JBH; Barros-Filho MC; Abreu FB; Cirilo PDR; Domingues MAC; Pontes A; Rogatto SR Mol Hum Reprod; 2018 Nov; 24(11):556-563. PubMed ID: 30376129 [TBL] [Abstract][Full Text] [Related]
11. Missense mutations in exon 2 of the MED12 gene are involved in IGF-2 overexpression in uterine leiomyoma. Di Tommaso S; Tinelli A; Malvasi A; Massari S Mol Hum Reprod; 2014 Oct; 20(10):1009-15. PubMed ID: 25015674 [TBL] [Abstract][Full Text] [Related]
12. Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors. Je EM; Kim MR; Min KO; Yoo NJ; Lee SH Int J Cancer; 2012 Sep; 131(6):E1044-7. PubMed ID: 22532225 [TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of AKT and the related biomarkers in uterine leiomyomas with MED12, HMGA2, and FH mutations. Xie J; Ubango J; Ban Y; Chakravarti D; Kim JJ; Wei JJ Genes Chromosomes Cancer; 2018 Oct; 57(10):485-494. PubMed ID: 29790226 [TBL] [Abstract][Full Text] [Related]
14. Subtype-Specific Tumor-Associated Fibroblasts Contribute to the Pathogenesis of Uterine Leiomyoma. Wu X; Serna VA; Thomas J; Qiang W; Blumenfeld ML; Kurita T Cancer Res; 2017 Dec; 77(24):6891-6901. PubMed ID: 29055020 [TBL] [Abstract][Full Text] [Related]
15. Systematic molecular and clinical analysis of uterine leiomyomas from fertile-aged women undergoing myomectomy. Äyräväinen A; Pasanen A; Ahvenainen T; Heikkinen T; Pakarinen P; Härkki P; Vahteristo P Hum Reprod; 2020 Oct; 35(10):2237-2244. PubMed ID: 32829387 [TBL] [Abstract][Full Text] [Related]
16. Cell cultures in uterine leiomyomas: rapid disappearance of cells carrying MED12 mutations. Nadine Markowski D; Tadayyon M; Bartnitzke S; Belge G; Maria Helmke B; Bullerdiek J Genes Chromosomes Cancer; 2014 Apr; 53(4):317-23. PubMed ID: 24446130 [TBL] [Abstract][Full Text] [Related]
17. Exomic landscape of MED12 mutation-negative and -positive uterine leiomyomas. Mäkinen N; Vahteristo P; Bützow R; Sjöberg J; Aaltonen LA Int J Cancer; 2014 Feb; 134(4):1008-12. PubMed ID: 23913526 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of MED12 mutations in uterine and extrauterine smooth muscle tumours. Matsubara A; Sekine S; Yoshida M; Yoshida A; Taniguchi H; Kushima R; Tsuda H; Kanai Y Histopathology; 2013 Mar; 62(4):657-61. PubMed ID: 23347103 [TBL] [Abstract][Full Text] [Related]
20. MED12 and uterine smooth muscle oncogenesis: State of the art and perspectives. Croce S; Chibon F Eur J Cancer; 2015 Aug; 51(12):1603-10. PubMed ID: 26037152 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]